Publication Name	World Journal of Hepatology
Manuscript ID	13735
Country	Germany

Received	2014-08-29 17:17
Peer-Review Started	2014-08-30 12:11
First Decision by Editorial Office Director
Return for Revision	2014-09-30 18:29
Revised	2014-10-21 00:00
Publication Fee Transferred
Second Decision by Editor	2014-12-11 17:24
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-12-17 16:11
Articles in Press	2014-12-17 16:11
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-03-20 12:12
Publish the Manuscript Online	2015-03-31 15:58

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Topic Highlights
Article Title	Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents
Manuscript Source	Invited Manuscript
All Author List	Kerstin Herzer and Guido Gerken
Funding Agency and Grant Number
Corresponding Author	Kerstin Herzer, MD, Associate Pro­fessor, Department of Gastroenterology and Hepatology, University Hospital Essen, Hufeland str. 55, 45122 Essen, Germany. kerstin.herzer@uk-essen.de
Key Words	Hepatitis C virus; Liver transplant; Inter­feron; Sofosbuvir; Simeprevir; Daclatasvir
Core Tip	In the liver transplant (LT) setting, graft loss due to hepatitis C virus (HCV) recurrence is a serious problem after LT. The former conventional treatment with pegylated interferon and ribavirin is unsatisfying, due to poor response rates and tolerability. With the first interferon-free regimens that are currently being approved for the treatment of patients with chronic HCV, 2014 marks the beginning of a new era of treatment options for HCV recurrence after LT. This review summarizes the current experience with and the expectations of the new direct-acting antiviral agents in the setting of LT.
Publish Date	2015-03-31 15:58
Citation	Herzer K, Gerken G. Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World J Hepatol 2015; 7(3): 532-538
URL	http://www.wjgnet.com/1948-5182/full/v7/i3/532.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i3.532

Full Article (PDF)	WJH-7-532.pdf
Full Article (Word)	WJH-7-532.doc
Manuscript File	13735-Review.docx
Answering Reviewers	13735-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13735-Conflict-of-interest statement.pdf
Copyright License Agreement	13735-Copyright assignment.pdf
Peer-review Report	13735-Peer review(s).pdf
Scientific Misconduct Check	13735-CrossCheck.jpg
Scientific Editor Work List	13735-Scientific editor work list.pdf